🇺🇸

US SEC Filing Intelligence

· daily

US Merger & Acquisition SEC Filings — March 20, 2026

The 12 filings reveal a surge in SPAC activity with 6 new IPOs or post-IPO events (SUMA, BHAV, Muzero, Fifth Era, Cayson, Pelican) and de-SPAC mergers advancing rapidly, including Pelican-Greenland closing March 24 and Nexstar's completed TEGNA acquisition on March 19, signaling robust M&A momentum in a tight window (March 12-24). Period-over-period trends show outlier strength in Merlin Labs (Inflection Point target) with 515% YoY revenue growth to $7.6M despite 35% wider net losses to $74.8M from opex and warrant surges, while B&G Foods' $110M Del Monte acquisition projects immediate EPS accretion ($0.08-0.12) at 5.5x EBITDA multiple. High redemptions (63% or 7.56M shares, $77.7M) in Pelican highlight cash drain risks in de-SPACs, contrasting full over-allotment exercises in SUMA (+2.25M units) and BHAV's $100M IPO. Media sector consolidation via Nexstar-TEGNA and TEGNA governance tweaks underscores strategic M&A, with neutral governance shifts in Horizon Quantum and Solaris financing potential Genco buy. Overall, bullish SPAC pipeline but mixed sentiment from redemptions and loss trends implies selective opportunities pre-close.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 20, 2026

Overnight SEC filings reveal robust M&A and SPAC activity, with healthcare deals like Prestige's $1.045B Breathe Right acquisition and Embecta's £150M Owen Mumford buyout signaling sector consolidation, while SPAC mergers (CoinShares, Pelican/Greenland, Einride/Legato) advance amid heavy redemptions (Pelican 63%). Revenue growth dominates period comparisons across 12/50 filings, averaging +80% YoY (e.g., Firefly +163%, Aeva +99%, Cellectis +62%), but 8/12 show widening net losses (avg +40%) due to R&D/opex surges and yield compression in BDCs (avg -0.9%). Margin expansions stand out (QIAGEN gross +1,330bps to 62.2%), contrasting compression elsewhere; activist pressure mounts on Lululemon (Wilson 8.4% stake, criticizing flat FY2026 outlook). Capital allocation leans toward buybacks (News Corp $1B program) and financing (Firefly $1.3B inflows), with forward catalysts clustered in late March (merger closings) and April (earnings, meetings). Portfolio-level: Tech/AI/space names outperform on revenue but lag on profitability; BDCs grow assets +72-83% but face yield/margin erosion. Actionable: Favor accretive M&A targets, monitor SPAC post-merger liquidity.

38 high priority 12 medium 50 total filings
· daily

DHS Homeland Security Contracts — March 19, 2026

DHS stream reveals $473M in active contracts dominated by CBP border security hardware (60% of value) and IT sustainment, with $186M largest to Rapiscan Systems (OSI Systems sub) for multi-energy portals. All five awards signal bullish multi-year revenue for detection firms and IT providers, with 40-70% already outlayed indicating execution momentum. Potential extensions to 2033 and $183M+ in unexercised options offer substantial upside amid firm fixed price structures.

5 total filings
· daily

VA Healthcare & Services Contracts — March 19, 2026

VA awarded $381M in contracts signaling robust demand for health IT infrastructure (Oracle, Deloitte) and recurring medical supplies (Medline), with $900M+ in total potential via options. Medline's back-to-back Jan/Feb 2026 awards ($138M total) highlight predictable prime vendor revenue, while IT/cyber deals offer multi-year upside to 2029. All firm-fixed-price structures favor incumbents but expose to cost risks; monitor outlays for execution momentum.

4 total filings
· daily

NASA & Space Contracts Intelligence — March 19, 2026

NASA's $85.4M obligated delivery order to Caltech (nonprofit) for JPL's PO.DAAC-2 operations reflects steady, non-competed funding for space science R&D, with $72.4M (85%) already outlayed from an $89.6M ceiling. Neutral signal limits direct equity upside, but $4.2M unexercised options and 2026 expiry offer monitoring points for continuity. Single-contract period shows concentration in JPL FFRDC support amid potential NASA priority shifts.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — March 19, 2026

Federal IT & Cybersecurity obligations totaled $1.66B across 7 contracts, with Leidos capturing 64% ($1.06B) from SSA for multi-year IT management, underscoring civilian agency demand. VA and DHS account for 45% of value via EHR interfaces, cyber transformation, and HR/infra support, providing revenue visibility to 2029. All signals bullish with $1.1B in potential options uplift, though firm fixed price structures pose execution risks.

7 total filings
· daily

New Federal Contractors — March 19, 2026

New federal contracts totaling $2.9B over March 19, 2026, underscore robust demand for IT services (e.g., Leidos' $1.06B SSA award) and security/detection systems (DHS/CBP wins), with 16/18 bullish signals dominated by long-term deals featuring $2B+ in potential option upside. Public firms like Leidos, General Dynamics, and OSI Systems (Rapiscan) gain multi-year revenue visibility through 2029+, while VA monthly medical supply awards to Medline signal recurring demand. Neutral signals limited to nonprofits (Caltech, Refugees Committee) with minimal equity impact.

18 total filings
· daily

Significant Contract Modifications ($10M+) — March 19, 2026

This single-day snapshot reveals $2.9B in significant federal contract modifications, dominated by IT services ($1.6B+ across top awards) signaling sustained government demand amid fiscal 2026 planning. Leidos captures 38% of value with two mega-awards ($1.13B total), bolstering defense/IT peers like General Dynamics and Oracle, while DHS/VA healthcare and security contracts provide multi-year revenue backstops through 2033. Investors should prioritize unexercised options ($1.5B+ potential) and extensions for upside, tempered by firm-fixed-price execution risks.

18 total filings
· daily

Contract Deobligations Alert — March 19, 2026

This one-day Contract Deobligations Alert reveals $2.9B in sustained federal obligations across 18 contracts, predominantly bullish for IT/services firms with Leidos capturing 39% ($1.13B total) via SSA and DHS awards. Long-term revenue visibility dominates, with 15 contracts extending beyond 2026 (up to 2033) and $2.1B+ in unexercised options signaling upside. Risks cluster around firm fixed price exposure (12/18 contracts) amid high outlays ($1.7B+ already spent), favoring public defense/IT names like Leidos, General Dynamics, and Oracle over nonprofits.

18 total filings
· daily

Contract Option Exercises — March 19, 2026

This snapshot reveals $2.9B in contract option exercises dominated by bullish signals (16/18) in IT services and security equipment, with Leidos securing the largest $1.1B SSA award and DHS/CBP driving 5 contracts totaling $473M. Public companies like Leidos (LDOS), General Dynamics (GD), OSI Systems (OSIS), and Oracle (ORCL) benefit from multi-year revenue visibility through 2029+, though firm fixed price (FFP) structures pose execution risks on 12/18 awards. Unexercised options exceed $2B across the portfolio, signaling medium-term growth potential amid steady federal demand in health IT, border security, and medical logistics.

18 total filings
· daily

All HHS Contracts — March 19, 2026

Two bullish HHS contracts totaling $414.7M obligated (potential $670.6M with options) signal multi-year revenue stability for health services providers via cost-plus structures minimizing risk. Wisconsin Physicians Service dominates with $319M CMS Medicare admin award, while Charles River adds $96M NIH preclinical support, highlighting HHS outsourcing trends. Unexercised options offer $252M upside amid extensions to 2028-2029.

2 total filings
· daily

Mega Contracts Monitor ($100M+) — March 19, 2026

Five mega contracts totaling $1.86B underscore strong federal demand for IT and health services, with Leidos securing the largest $1.06B SSA deal amid 82% outlay progress. All awards are bullish, featuring long durations (avg. potential end 2028+), $1.36B in combined unobligated options, and focus on civilian agencies (SSA, CMS, VA, DHS, Education). Public parents Leidos Holdings, OSI Systems, Oracle, and General Dynamics gain multi-year revenue visibility, though firm-fixed pricing dominates (4/5 contracts).

5 total filings
· daily

High-Value Federal Grants ($5M+) — March 19, 2026

This one-day snapshot of 18 high-value federal contracts totaling $2.9B underscores bullish momentum for IT services and health/security contractors, with Leidos securing the largest $1.1B combined awards from SSA and DHS. Firm fixed price structures dominate (12/18), offering revenue visibility but execution risks, while options provide $2B+ upside potential across portfolios. Institutional investors should prioritize public equities like Leidos (LDOS), OSI Systems (OSIS), and General Dynamics (GD) for steady gov revenue amid long-term extensions to 2033.

18 total filings
· daily

General Federal Contracts — March 19, 2026

Leidos dominates with a $1.06B SSA IT contract (37% of total value), signaling robust civilian IT demand and multi-year revenue stability amid $2.9B in awards. DHS/CBP and VA drive security/IT and medical supply contracts, with 16/18 bullish signals highlighting long-term options worth $2B+ upside. Firm fixed price structures prevail (70% of contracts), exposing winners to cost risks but locking in predictable cash flows through 2026-2033.

18 total filings
· daily

All NASA Contracts — March 19, 2026

NASA's $85.4M obligation to California Institute of Technology for PO.DAAC-2 operations signals stable funding for space science data archiving via JPL FFRDC, with $72.4M already outlayed and $4.2M in unexercised options. As a non-competed, nonprofit contract ending 2026-09-30, it offers neutral direct equity impact but underscores continuity in physical oceanography R&D. Investors face execution risks from task order dependence amid potential NASA priority shifts, with extension potential warranting monitoring.

1 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Consumer Staples stream (though diverse with funds, biotechs, REITs), proxy statements dominate (24/50, neutral sentiment) signaling robust governance ahead of clustered April-May 2026 annual meetings. Financial reporters (10-K/8-K, 18/50) show mixed YoY revenue growth averaging +25% (e.g., Vericel +20% CAGR, Satellogic +38%, electroCore +27%) but persistent net losses narrowing in 7/12 cases (e.g., SentinelOne op inc positive swing). Margin trends mixed with expansions (Signet adj op inc +3.4% FY, Vericel gross 74%) offset by compressions (Signet Q4 -60bps). Capital allocation leans positive: dividend hikes (Signet +17% to $0.35/sh, Modiv $0.10/mth), buybacks (Mount Logan $10M program), accretive M&A (Mount Logan +30% FRE). Forward guidance cautious (Signet FY27 SSS -1.25% to +2.5%) amid Q4 softness, but clinical catalysts in biotechs. Portfolio-level: Stable dividends vs reinvestment, low insider trading signals conviction, watch proxy outcomes and Q1 earnings for consumer resilience.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — March 19, 2026

Across 50 filings in the USA S&P 500 Industrials stream (broadly including transportation, construction, and adjacent sectors amid mixed data), overarching themes include robust revenue growth in transportation leaders like FedEx (+8% YoY Q3 to $24B) and strategic pivots (UPS prioritizing high-value volume), contrasted by widening losses in biotechs (Eledon +26% net loss YoY) and operational declines (Gemini trading volume -30% QoQ). Period-over-period trends show 12/50 companies with double-digit YoY revenue gains averaging +45% (e.g., argenx +90%, Eton +83% Q4), but 8 with margin compression or expense surges (avg +30-40% OpEx); adjusted EPS grew in outperformers like Darden (+5.4%) and FedEx (+16.4%). Capital allocation favors shareholder returns with 15+ dividend declarations (e.g., Global Net Lease prefs at coupon rates) and buybacks (GrowGen $10M, Darden $127M Q3). Proxy season dominates with 20+ DEF/DEFA14A filings clustering AGMs in May 2026, featuring governance votes and comp approvals. Forward-looking signals positive: FedEx raised FY26 guidance (rev 6-6.5%, EPS $19.30-20.10), Eton >$110M 2026 rev; risks from earnings delays (Armata) and trial postponements (Catalyst to May 18). Portfolio implication: overweight transportation (FedEx/UPS resilience), monitor biotech turnarounds, capitalize on May catalysts.

24 high priority 26 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — March 19, 2026

S&P 500 Energy sector filings from March 19, 2026, reveal a mix of proactive capital market access and shareholder governance activities, with Occidental Petroleum (OXY) dominating positive narratives through robust 2025 performance highlights including $10.5B operating cash flow, $4.3B free cash flow before working capital, $575M cost reductions, record production, and safety TRIR of 0.07 despite YoY challenging commodity prices. Cheniere Energy (LNG) signals strong liquidity via $1.75B senior notes issuance (5.200% due 2036, 6.000% due 2056), with registration rights underscoring structured debt management. Valero Energy (VLO) filings focus on standard proxy processes for its May 7 AGM, showing neutral sentiment and no financial trends disclosed. Aggregated period-over-period insights from OXY highlight debt reduction ($4B direct + $7B from OxyChem divestiture), resource base expansion to 16.5B BOE (up from 8B in 2015, +106%), and dividend growth (8%+ quarterly hike, +44% since 2023 CrownRock deal announcement), painting a picture of resilient capital allocation amid sector headwinds. Proxy season activation across OXY and VLO sets up near-term catalysts, while LNG's financing bolsters balance sheet for potential growth. No insider trading, guidance changes, or M&A details emerged, but positive sentiments from key filings (LNG/OXY) outpace neutrals, implying sector stability with pockets of outperformance.

3 high priority 2 medium 5 total filings
· daily

S&P 500 Financials Sector SEC Filings — March 19, 2026

Across 50 diverse SEC filings (despite 'S&P 500 Financials' stream label, spanning industrials, biotech, tech, mining, and limited true financials like BDCs/REITs), sentiment skews mixed with 14/50 positive, 16 mixed, and robust YoY revenue growth averaging +35% in 18 reporting companies (e.g., Micron +196%, Cardinal +45%, SUNation +26%) offset by declines in 6 (e.g., Solo Brands -30%, DarioHealth -17%). EBITDA/margin expansions prevalent in 12 cases (e.g., SUNation + to $2.5M, Aebi Schmidt Q4 +31%), but net losses widened in 10 biotechs/miners amid opex surges; cash strengthened in 15 (avg +40% YoY where trended). Capital allocation favors dividends (8 declarations steady, e.g., Chicago Atlantic BDC $0.34/share x6 quarters) and buybacks/debt paydowns (News Corp $1B program, SUNation debt -57%). M&A/SPAC activity high (RYVYL 99% merger support, Vine Hill EGM), proxy/AGMs cluster Q2 2026. Portfolio trends signal resilient growth amid costs, with BDC/REIT stability contrasting volatile small caps; actionable now: favor high-conviction growth like Micron/Accenture, monitor merger catalysts.

23 high priority 27 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — March 19, 2026

Across 50 US SEC filings dated March 19, 2026, dominant themes include aggressive capital raising via equity/debt offerings (e.g., SAB, Reviva, Humacyte, Wolfspeed), M&A and SPAC extensions/amendments (MLCI acquisition, Pyrophyte to Apr 2027, Movano-Corvex merger), credit facility amendments tied to pending mergers (AES, Dayton Power), and board/governance changes (appointments at CVS, RGA, resignations at TripAdvisor, LiveRamp). Period-over-period trends reveal revenue pressures in hospitality (RCI Hospitality -5.5% YoY to $279.4M, Bombshells -29.2% YoY; Ashford pro forma -1.5% YoY to $1.15B) but balance sheet improvements via asset sales/debt paydowns (Ashford $56.8M sale, DevvStream $5.9M net debt reduction). Positive catalysts include accretive deals (Collegium AZSTARYS $650M for >$50M H2 2026 revenue, MLCI +30% FRE), debt refinancings (Wolfspeed $475.9M lower-cost notes), and JV formations (Horizon $100M). Financial stress signals in cannabis (Cannabist forbearance to Mar 25) and microcaps (Scorpius $248K notes) contrast with biotech fundraising for trials (SAB-142, brilaroxazine). Portfolio-level: 12/50 filings show financing stress (debt/notes/forbearance), but 8 accretive M&A/JVs signal consolidation; watch Q2/Q3 closings for alpha.

50 high priority 50 total filings